 Antibodies, Antineutrophil Cytoplasmic
"Antibodies, Antineutrophil Cytoplasmic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Autoantibodies directed against cytoplasmic constituents of POLYMORPHONUCLEAR LEUKOCYTES and/or MONOCYTES. They are used as specific markers for WEGENER GRANULOMATOSIS and other diseases, though their pathophysiological role is not clear. ANCA are routinely detected by indirect immunofluorescence with three different patterns: c-ANCA (cytoplasmic), p-ANCA (perinuclear), and atypical ANCA.
| Descriptor ID |
D019268
|
| MeSH Number(s) |
D12.776.124.486.485.114.323.190 D12.776.124.790.651.114.323.190 D12.776.377.715.548.114.323.190 D23.101.050
|
| Concept/Terms |
Antibodies, Antineutrophil Cytoplasmic- Antibodies, Antineutrophil Cytoplasmic
- Antineutrophil Cytoplasmic Antibody
- Antibody, Antineutrophil Cytoplasmic
- Cytoplasmic Antibody, Antineutrophil
- Anti-Neutrophil Cytoplasmic Antibody
- Anti Neutrophil Cytoplasmic Antibody
- Antibody, Anti-Neutrophil Cytoplasmic
- Cytoplasmic Antibody, Anti-Neutrophil
- Anti-Neutrophil Cytoplasmic Antibodies
- Anti Neutrophil Cytoplasmic Antibodies
- Antibodies, Anti-Neutrophil Cytoplasmic
- Cytoplasmic Antibodies, Anti-Neutrophil
- ANCA
- Antineutrophil Cytoplasmic Antibodies
- Cytoplasmic Antibodies, Antineutrophil
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Antineutrophil Cytoplasmic".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Antineutrophil Cytoplasmic".
This graph shows the total number of publications written about "Antibodies, Antineutrophil Cytoplasmic" by people in this website by year, and whether "Antibodies, Antineutrophil Cytoplasmic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 1 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 2004 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 0 | 2 | | 2007 | 2 | 1 | 3 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 1 | 2 | | 2012 | 2 | 0 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Antineutrophil Cytoplasmic" by people in Profiles.
-
McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i123-31.
-
McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transplant. 2015 Apr; 30 Suppl 1:i171-81.
-
Cao Y, Liu K, Tian Z, Hogan SL, Yang J, Poulton CJ, Falk RJ, Li W. PTPN22 R620W polymorphism and ANCA disease risk in white populations: a metaanalysis. J Rheumatol. 2015 Feb; 42(2):292-9.
-
Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012 Oct; 64(10):3452-62.
-
Cao Y, Yang J, Colby K, Hogan SL, Hu Y, Jennette CE, Berg EA, Zhang Y, Jennette JC, Falk RJ, Preston GA. High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis. PLoS One. 2012; 7(8):e42783.
-
Roth AJ, Brown MC, Smith RN, Badhwar AK, Parente O, Chung Hc, Bunch DO, McGregor JG, Hogan SL, Hu Y, Yang JJ, Berg EA, Niles J, Jennette JC, Preston GA, Falk RJ. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol. 2012 Mar; 23(3):545-55.
-
Tomasson G, Lavalley M, Tanriverdi K, Finkielman JD, Davis JC, Hoffman GS, McCune WJ, St Clair EW, Specks U, Spiera R, Stone JH, Freedman JE, Merkel PA. Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis. J Rheumatol. 2011 Jun; 38(6):1048-54.
-
Joy MS, Boyette T, Hu Y, Wang J, La M, Hogan SL, Stewart PW, Falk RJ, Dooley MA, Smith PC. Effects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritis. Eur J Clin Pharmacol. 2010 Nov; 66(11):1119-30.
-
Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, Nachman PH. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int. 2009 Sep; 76(6):644-51.
-
Joy MS, Hilliard T, Hu Y, Hogan SL, Wang J, Falk RJ, Smith PC. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother. 2009 Jun; 43(6):1020-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|